Insider Sale: BioLife Solutions, Inc. (NASDAQ: BLFS) CFO Sells 569 Shares
BioLife Solutions, Inc. (NASDAQ: BLFS – Get a rating) CFO troy wichterman sold 569 shares in a trade that took place on Friday, September 23. The stock was sold at an average price of $21.91, for a total transaction of $12,466.79. Following the transaction, the CFO now directly owns 45,352 shares of the company, valued at approximately $993,662.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website.
Troy Wichterman also recently completed the following trade(s):
- On Tuesday August 16, Troy Wichterman sold 116 shares of BioLife Solutions. The stock was sold at an average price of $24.81, for a total transaction of $2,877.96.
BioLife Solutions trades down 2.9%
Shares of BioLife Solutions traded down $0.64 during Monday trading hours, hitting $21.59. The company’s stock had a trading volume of 317,473 shares, compared to an average volume of 400,451. BioLife Solutions, Inc. has a 1-year low of $10.40 and a 1-year high of $58.80 . The company has a fifty-day moving average of $22.43 and a 200-day moving average of $18.36. The company has a market capitalization of $919.84 million, a PE ratio of -9.60 and a beta of 1.91. The company has a quick ratio of 2.54, a current ratio of 3.55 and a leverage ratio of 0.02.
Wall Street analysts predict growth
Separately, Cowen lowered its price target on BioLife Solutions stock to $29.00 in a Monday, August 15 research report. One research analyst has rated the stock with a sell rating and three have assigned the company a buy rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.
Institutional investors weigh in on BioLife solutions
Several large investors have recently changed their positions in the company. KBC Group NV acquired a new stake in BioLife Solutions during the 2nd quarter for a value of $36,000. Point72 Hong Kong Ltd acquired a new stake in BioLife Solutions during Q1 valued at $36,000. Lazard Asset Management LLC acquired a new stake in BioLife Solutions during Q1 valued at $45,000. Captrust Financial Advisors increased its stake in BioLife Solutions by 714.2% during the second quarter. Captrust Financial Advisors now owns 3,949 shares of the medical equipment supplier valued at $55,000 after buying 3,464 additional shares last quarter. Finally, Mutual of America Capital Management LLC increased its stake in BioLife Solutions by 18.7% during the second quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment supplier valued at $71,000 after buying 808 additional shares last quarter. Institutional investors and hedge funds own 86.69% of the company’s shares.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures and provides biomanufacturing tools and services for the cell and gene therapy industry in the United States, Canada, Europe, Middle East, Africa and internationally. The company’s products are used in basic and applied research and in the commercial manufacture of biological therapies.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider BioLife Solutions, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and BioLife Solutions didn’t make the list.
Although BioLife Solutions currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here